|
Patent landscape, scope, and claims: |
Scope & claims of US Patent 8,133,893 (trazodone alkylating-substance impurity limits) and how the patent estate shapes US generic and formulation risk
US Patent 8,133,893 is a trazodone hydrochloride impurity-control patent. Its core claim set is directed to trazodone (or trazodone HCl) having specified ultra-low levels (ppm thresholds) of a defined list of alkylating substances (explicit named chemical impurities). Dependent claims narrow the impurity lists and numeric limits. The second pillar is a manufacturing/process claim that ties the impurity spec to a particular two-phase (organic/aqueous) mixing and heating route using base, optionally a phase-transfer catalyst, and defined solvent/base/catalyst options and process ranges.
The practical effect: the patent does not claim a new active ingredient, a new therapeutic use, or a new dosage form. It claims product-by-impurity-spec and process conditions that are designed to control alkylating impurities during extraction/phase transfer workups. For US entry, the main infringement pathway is Paragraph IV risk if a proposed generic’s COA (or testing under FDA/ANDA validation conditions) shows alkylating substances above the claimed ppm limits, or if its manufacturing process uses the claimed two-phase/heating/catalyst framework and does not prevent those impurities from exceeding the thresholds.
What alkylating substances are covered by US Patent 8,133,893 and how do the ppm limits define infringement?
Direct answer: The patent covers trazodone or trazodone hydrochloride containing alkylating substances in a total amount below specific ppm thresholds, where the “alkylating substances” are limited to a closed list of explicitly named compounds (and mixtures of them). The claim is triggered by meeting both: (i) the product identity (trazodone or trazodone HCl) and (ii) the impurity presence within the numeric limits for the named alkylating substances.
Claim 1 impurity spec (open list of named alkylating substances, capped total)
Claim 1 covers:
- “Trazodone or trazodone hydrochloride”
- “wherein alkylating substances are present in a total amount which is less than 15 ppm”
- “alkylating substances are selected from the group consisting of” the following named impurities:
- 2,2-dichloroethylamine
- 1-bromo-3-chloropropane
- N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine
- 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one
- 3-chloro-N,N′-dichloroethyl-aniline
- 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]-triazolo[4,3-a]pyridin-3-one
- 2,2-dibromoethylamine
- 1,3-dichloropropane
Infringement framing: To infringe claim 1, an accused product must be trazodone/trazodone HCl and test positive for these compounds at aggregate levels that satisfy “less than 15 ppm” (as claimed). Because the numeric limitation is “less than,” the claim is favorable to patentees only to the extent accused products produce sufficiently low levels. If a generic produces higher levels, claim 1 is not met; if it produces lower levels, claim 1 is met.
Dependent claims tighten the total ppm cap
- Claim 2: total alkylating substances < 10 ppm
- Claim 3: total alkylating substances < 2.5 ppm
Claim 4 narrows the impurity universe (subset selection)
- Claim 4: total < 15 ppm (per claim 1 incorporation) but alkylating substances are limited to a subset:
- 2,2-dichloroethylamine
- 1-bromo-3-chloropropane
- N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine
- and mixtures thereof
Claim 5 introduces per-impurity “each” limits
- Claim 5: “less than 1 ppm of each of said alkylating substances” (and by incorporation, the total is also “< 15 ppm” from claim 1 unless the claim set is otherwise structured in the written text; the safe reading is that claim 5 is even narrower by per-compound requirement)
Claims 6–7 narrow both selection and per-impurity limits
- Claim 6: per-impurity < 1 ppm, impurity selection can include the full list (1–8)
- Claim 7: per-impurity < 1 ppm, impurity selection limited to:
- 2,2-dichloroethylamine
- 1-bromo-3-chloropropane
- N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine
- and mixtures thereof
Claim 8: composition claim mirrors the impurity-control product claim
- Claim 8: pharmaceutical composition comprising trazodone HCl “according to claim 1” plus excipient(s).
Practical scope note: Claim 8 expands from active drug substance to finished composition, but it is still tethered to the impurity spec of claim 1. A generic that meets the impurity limits could fall within claim 8 depending on excipient and product-by-spec interpretation.
How broad is the manufacturing-process protection in US 8,133,893?
Direct answer: The patent protects a process for producing trazodone/trazodone HCl via an organic/aqueous two-phase mixing with base and a heating step of at least 40°C for at least 30 minutes, tied to achieving the <15 ppm impurity spec. The claim is then broadened and narrowed through solvent choices, base choices, phase-transfer catalyst options, and quantitative process ranges.
Claim 9: the core two-phase process tied to the impurity limit
Claim 9 requires:
- (a) preparing an organic phase comprising trazodone in at least one organic solvent
- (b) preparing an aqueous phase comprising at least one basic compound
- (c) mixing aqueous into organic
- (d) heating at ≥ 40°C for ≥ 30 minutes
- (e) recovering trazodone
- (f) optionally treating recovered trazodone with hydrochloric acid to obtain trazodone HCl
- with the resulting material having < 15 ppm of alkylating substances (as defined in claim 1).
Dependent claim range tightening (10 ppm, 2.5 ppm, 1 ppm)
- Claim 10: product < 10 ppm
- Claim 11: product < 2.5 ppm
- Claim 12: product < 1 ppm
Solvent choices (claims 13–14)
- Claim 13: organic solvent selected from alcohol, ether, hydrocarbon, ketone, ester (broad solvent class coverage).
- Claim 14: non-exhaustive examples narrowed to a long list including:
- alcohols: ethyl alcohol, propyl alcohol, isobutyl alcohol, hexyl alcohol, benzyl alcohol
- ethers: ethyl ether, propyl ether
- hydrocarbons: toluene, benzene, xylene
- ketones: acetone, methyl ethyl ketone, methyl isobutyl ketone
- ester: ethyl acetate
Trazodone loading and phase quantities (claims 15, 20)
- Claim 15: organic phase comprises trazodone in 10 g to 50 g per 100 g organic phase
- Claim 20: aqueous phase added 30 g to 100 g per 100 g organic phase
Basic compound categories (claims 16–19)
- Claim 16: aqueous phase includes inorganic base, organic base, or mixtures
- Claim 17: inorganic base examples include sodium/potassium hydroxide, carbonates, bicarbonates, phosphates, ammonium hydroxide, magnesium oxide, hydrazine, hydroxylamine
- Claim 18: organic bases are aliphatic amines or aromatic amines
- Claim 19: base added amount 0.05 to 1 mol per mol of trazodone
Phase transfer catalyst option (claims 21–27)
- Claim 21: aqueous phase comprises a phase transfer catalyst
- Claim 22: catalyst selected from quaternary ammonium salts or quaternary phosphonium salts
- Claim 23–24: long explicit quaternary ammonium salt list including tetrabutyl ammonium salts, benzyl triethyl/trimethyl ammonium salts, benzyl tributyl ammonium bromide/chloride, cetyl pyridinium salts, and many others
- Claim 25: quaternary phosphonium salt list including benzyl/butyl/ethyl triphenyl phosphonium variants, tributyl/hexadecyl variants, methyl triphenyl phosphonium bromide, tetrabutyl phosphonium bromide, tetraphenyl phosphonium bromide
- Claim 26: catalyst loading 0.05 g to 0.5 g per 100 g aqueous phase
- Claim 27: heating condition expanded:
- heating temperature between 40°C and boiling point of organic/aqueous mixture
- heating time between 30 min and 300 min
Process-infringement logic: A process using different chemistry may avoid the claim; a process that meets all required steps and yields a product meeting the impurity spec can trigger infringement. Because claim 9 requires “wherein said trazodone or trazodone hydrochloride comprises less than 15 ppm,” the process must also be capable of producing the claimed low-impurity product.
What is the legal and commercial risk for US generics attempting to launch after US Patent 8,133,893?
Direct answer: The risk is driven by (1) product-by-impurity-spec coverage and (2) process conditions aligned to extraction/phase-transfer workups that produce trazodone/trazodone HCl with alkylating impurities below set ppm thresholds. A generic that uses a different purification route or controls impurities through alternative steps may design around, but any reliance on the same two-phase mixing with base and heating plus optional phase-transfer catalysts can recreate risk.
Key “infringement vectors” created by these claims
- Testing/COA alignment: If the generic’s finished drug substance or intermediate for API release is tested for the defined alkylating substances and the aggregate/per-compound levels fall within the claimed limits, the generic can satisfy product-by-spec claim elements.
- Process similarity: If the manufacturing method mirrors the claim 9 sequence, a patentee can argue process infringement even if the generic’s formulation differs.
- Composition coverage (claim 8): Final dosage forms are not claimed explicitly, but any pharmaceutical composition comprising trazodone HCl according to claim 1 can be in scope.
Paragraph IV practical take
- If US Patent 8,133,893 is listed in the Orange Book for an approved trazodone HCl product, ANDA filers often must address it via a Paragraph IV certification. The litigation tends to turn on (i) claim construction of impurity measurement and units, and (ii) whether the proposed manufacturing process and expected impurity profile meet the “less than” limitations for the named alkylating substances.
How strong is the patent estate for impurity-control claims like US 8,133,893?
Direct answer: Strength is high on claim specificity (closed list of impurities, numeric ppm limits, and a defined process outline with optional phase-transfer catalyst options), but enforcement depends on infringement proof tied to actual impurity levels in the accused product and actual process steps used by the accused manufacturer.
Claim specificity advantages
- Closed list of impurities: the named “alkylating substances” are exhaustively listed in claim 1.
- Numerical cutoffs: multiple thresholds (15, 10, 2.5, 1 ppm total or per compound).
- Process anchor points: two-phase mixing, heating ≥40°C for ≥30 min, defined solvent classes/examples, defined base classes/examples, and explicit catalyst families and ranges.
Claim weaknesses for enforcement (structural)
- “Less than” requirements: if an accused product does not meet the low-ppm spec, it may avoid the impurity-spec product claims.
- Measurement/assay mapping: enforcement requires credible matching of the accused impurity species to the defined list and measuring them at ppm levels under a method that yields comparable results.
- Process design-around: alternative purification routes that avoid the claimed organic/aqueous/base mixing and heating with phase-transfer catalysts can reduce risk.
How do these claims compare with typical trazodone patent coverage (use, polymorph, dosage form)?
Direct answer: US 8,133,893 is atypical relative to standard small-molecule patent estates dominated by new compositions, polymorphs, or method-of-use claims. It is an impurity-control and manufacturing-process patent tied to specific genotoxic/alkylating impurity species and ppm thresholds.
What it does not cover (based on claim text provided)
- No new indication or method-of-use claims
- No specific solid form (polymorph/crystal form) claims
- No dosage form claims (tablet, capsule, etc.) in the text provided
- No new chemical synthesis intermediate claims beyond the listed process operations
Claim-by-claim scope map for US 8,133,893 (what each claim adds)
| Claim |
Subject |
Added limitations over claim 1/9 baseline |
Practical scope consequence |
| 1 |
Product (trazodone or HCl) |
Total alkylating substances < 15 ppm; impurity list = 8 named compounds |
Core impurity-control product claim |
| 2 |
Product |
Total < 10 ppm |
Narrower product spec |
| 3 |
Product |
Total < 2.5 ppm |
Narrower product spec |
| 4 |
Product |
Alkylating substances subset (3 listed) |
Narrows impurity universe; still <15 ppm total |
| 5 |
Product |
Each impurity < 1 ppm |
Narrows both total and per-component |
| 6 |
Product |
Each <1 ppm; impurity list can be all 8 |
Tightens per-compound requirement while preserving full list |
| 7 |
Product |
Each <1 ppm; impurity subset (3 listed) |
Tightest with narrow impurity universe |
| 8 |
Composition |
Composition includes excipient(s); drug must be “according to claim 1” |
Extends product impurity spec to formulations |
| 9 |
Process |
Two-phase organic/aqueous with base; mixing; heating ≥40°C for ≥30 min; optional HCl salt; product <15 ppm |
Core process claim tied to impurity outcome |
| 10 |
Process |
Product <10 ppm |
Narrower outcome spec |
| 11 |
Process |
Product <2.5 ppm |
Narrower outcome spec |
| 12 |
Process |
Product <1 ppm |
Narrower outcome spec |
| 13–14 |
Process |
Organic solvent class (then exemplified list) |
Defines solvent choices that stay in scope |
| 15 |
Process |
Trazodone loading 10–50 g per 100 g organic phase |
Narrows operating regime |
| 16–19 |
Process |
Base types and amount (0.05–1 mol/mol) |
Narrows aqueous phase chemistry |
| 20 |
Process |
Aqueous phase 30–100 g per 100 g organic phase |
Narrows phase ratio |
| 21–26 |
Process |
Optional phase-transfer catalyst; detailed catalyst family lists; loading 0.05–0.5 g per 100 g aqueous |
Adds catalyst-based route coverage |
| 27 |
Process |
Heating temp up to boiling; time 30–300 min |
Broadens within specified heating windows |
What design-arounds are suggested by the claim language (without inventing facts)?
Direct answer: The most direct design-arounds are those that (i) avoid manufacturing conditions that match claim 9’s required steps and (ii) ensure impurity profiles are outside the claimed “less than” product-by-spec boundaries for the named alkylating substances.
Manufacturing changes to reduce process-match risk
- Avoid the specific organic/aqueous mixing with base and the claimed heating window (claim 9 elements).
- Avoid use of the claimed phase-transfer catalyst categories and specific catalyst families listed (if claiming requires it only as an option, elimination helps but still must avoid the rest of the steps).
- Use solvents and aqueous chemistry outside the lists and ranges, or phase ratios outside claim 15 and 20.
Impurity control strategy
- Ensure that the relevant alkylating substances are not measured as falling within the claimed ppm thresholds for the defined list (product-by-spec scope hinges on impurity levels matching the “less than” limitations).
Key Takeaways
- US Patent 8,133,893 is an impurity-control patent for trazodone/trazodone HCl, using a closed list of named alkylating substances and ppm-based thresholds.
- The strongest claim coverage is claim 1 (total <15 ppm) and claim 9 (two-phase base/organic mixing, heating ≥40°C for ≥30 min, optional HCl salt, with product <15 ppm).
- Dependent claims narrow total ppm, per-impurity limits, and subset selection of impurities.
- Claim 8 extends the impurity-spec to pharmaceutical compositions.
- For generic risk, infringement hinges on both (i) impurity testing results for the named species and (ii) whether the generic’s process matches the claim 9 framework and yields an API meeting the claimed impurity spec.
FAQs
-
Can a generic avoid US 8,133,893 by using a different solvent system?
Risk reduces if the process does not satisfy claim 9’s solvent-related limitations and overall step sequence used to generate the claimed low-ppm impurity profile.
-
Does US 8,133,893 cover finished dosage forms like tablets and capsules?
The claims provided include a pharmaceutical composition claim (claim 8) that covers compositions with trazodone HCl meeting claim 1 impurity conditions, but the text does not specify a dosage form.
-
What matters more in litigation, impurity test results or manufacturing process steps?
Both. The product-by-spec claims turn on measured impurity levels for the named alkylating substances. The process claims turn on whether the accused route matches the claimed two-phase/base/heating framework and yields the impurity spec.
-
Are phase-transfer catalysts required for infringement?
No. They are optional in claim 9 because phase transfer catalyst appears in dependent claims (claims 21–26). A route without such catalysts can still fall within claim 9 if all other required steps and impurity outcome are met.
-
How do the “less than” ppm limits affect design-around strategies?
Because the claims require impurity levels below specific ppm thresholds, products that do not achieve those low levels for the named alkylating substances may fall outside the product claims, while products that do may increase risk.
References
No sources were cited because only the claim language provided was used.
More… ↓
⤷ Start Trial
|
